Quercetin as an Anti-Diabetic Agent in Rodents—Is It Worth Testing in Humans?
| cris.lastimport.scopus | 2025-10-23T06:57:38Z | |
| cris.virtual.author-orcid | 0000-0002-9067-6682 | |
| cris.virtual.author-orcid | 0000-0002-6828-0534 | |
| cris.virtual.author-orcid | 0000-0003-3827-2282 | |
| cris.virtualsource.author-orcid | ff566057-8099-4bac-bd4c-896c46beaa7c | |
| cris.virtualsource.author-orcid | daf06652-dcef-4aa8-b66a-bdb14028e85d | |
| cris.virtualsource.author-orcid | 1978986a-7b21-41ea-8424-a6724d96b11b | |
| dc.abstract.en | Quercetin is a biologically active flavonoid compound that exerts numerous beneficial effects in humans and animals, including anti-diabetic activity. Its action has been explored in rodent models of type 1 and type 2 diabetes. It was revealed that quercetin mitigated diabetes-related hormonal and metabolic disorders and reduced oxidative and inflammatory stress. Its anti-diabetic effects were associated with advantageous changes in the relevant enzymes and signaling molecules. Quercetin positively affected, among others, superoxide dismutase, catalase, glutathione peroxidase, glucose transporter-2, glucokinase, glucose-6-phosphatase, glycogen phosphorylase, glycogen synthase, glycogen synthase kinase-3β, phosphoenolpyruvate carboxykinase, silent information regulator-1, sterol regulatory element-binding protein-1, insulin receptor substrate 1, phosphoinositide 3-kinase, and protein kinase B. The available data support the conclusion that the action of quercetin was pleiotropic since it alleviates a wide range of diabetes-related disorders. Moreover, no side effects were observed during treatment with quercetin in rodents. Given that human diabetes affects a large part of the population worldwide, the results of animal studies encourage clinical trials to evaluate the potential of quercetin as an adjunct to pharmacological therapies. | |
| dc.affiliation | Wydział Medycyny Weterynaryjnej i Nauk o Zwierzętach | |
| dc.affiliation.institute | Katedra Fizjologii, Biochemii i Biostruktury Zwierząt | |
| dc.affiliation.institute | Katedra Zoologii | |
| dc.contributor.author | Szkudelski, Tomasz | |
| dc.contributor.author | Szkudelska, Katarzyna | |
| dc.contributor.author | Łangowska, Aleksandra | |
| dc.date.access | 2025-08-13 | |
| dc.date.accessioned | 2025-08-13T12:06:48Z | |
| dc.date.available | 2025-08-13T12:06:48Z | |
| dc.date.copyright | 2025-07-31 | |
| dc.date.issued | 2025 | |
| dc.description.abstract | <jats:p>Quercetin is a biologically active flavonoid compound that exerts numerous beneficial effects in humans and animals, including anti-diabetic activity. Its action has been explored in rodent models of type 1 and type 2 diabetes. It was revealed that quercetin mitigated diabetes-related hormonal and metabolic disorders and reduced oxidative and inflammatory stress. Its anti-diabetic effects were associated with advantageous changes in the relevant enzymes and signaling molecules. Quercetin positively affected, among others, superoxide dismutase, catalase, glutathione peroxidase, glucose transporter-2, glucokinase, glucose-6-phosphatase, glycogen phosphorylase, glycogen synthase, glycogen synthase kinase-3β, phosphoenolpyruvate carboxykinase, silent information regulator-1, sterol regulatory element-binding protein-1, insulin receptor substrate 1, phosphoinositide 3-kinase, and protein kinase B. The available data support the conclusion that the action of quercetin was pleiotropic since it alleviates a wide range of diabetes-related disorders. Moreover, no side effects were observed during treatment with quercetin in rodents. Given that human diabetes affects a large part of the population worldwide, the results of animal studies encourage clinical trials to evaluate the potential of quercetin as an adjunct to pharmacological therapies.</jats:p> | |
| dc.description.accesstime | at_publication | |
| dc.description.bibliography | il., bibliogr. | |
| dc.description.finance | publication_nocost | |
| dc.description.financecost | 0,00 | |
| dc.description.if | 4,9 | |
| dc.description.number | 15 | |
| dc.description.points | 140 | |
| dc.description.version | final_published | |
| dc.description.volume | 26 | |
| dc.identifier.doi | 10.3390/ijms26157391 | |
| dc.identifier.eissn | 1422-0067 | |
| dc.identifier.issn | 1661-6596 | |
| dc.identifier.uri | https://sciencerep.up.poznan.pl/handle/item/4202 | |
| dc.identifier.weblink | https://www.mdpi.com/1422-0067/26/15/7391 | |
| dc.language | en | |
| dc.relation.ispartof | International Journal of Molecular Sciences | |
| dc.relation.pages | art. 7391 | |
| dc.rights | CC-BY | |
| dc.sciencecloud | send | |
| dc.share.type | OPEN_JOURNAL | |
| dc.subject.en | quercetin | |
| dc.subject.en | diabetes | |
| dc.subject.en | metabolism | |
| dc.subtype | ReviewArticle | |
| dc.title | Quercetin as an Anti-Diabetic Agent in Rodents—Is It Worth Testing in Humans? | |
| dc.type | JournalArticle | |
| dspace.entity.type | Publication | |
| oaire.citation.issue | 15 | |
| oaire.citation.volume | 26 |